Scroll Top

Profluents open source AI CRISPR tool brings gene editing to the masses


Open source changed the technology industry now imagine what everyone could do if they had open access to editing the human genome at scale …


Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trendsconnect, watch a keynote, or browse my blog.

Artificial Intelligence (AI) enabled protein design company Profluent has leveraged AI to design an open-source gene editor called OpenCRISPR-1, demonstrating the technology can be used to create molecules with the power to edit human DNA. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, developed more than a decade ago, allows scientists to modify DNA sequences within living organisms precisely. Potential applications range from treatments for genetic disorders to researching disease mechanisms.


Disney hopes children will love its new autonomous story-telling robots


The molecules it designs are fully synthetic and do not exist in nature, in contrast to previous technologies in gene editing, such as CRISPR-Cas9.

The company is open-sourcing OpenCRISPR-1 for free ethical research and commercial use and published the science behind the protein’s development in a preprint publication.

“Attempting to edit human DNA with an AI-designed biological system was a scientific moonshot,” Ali Madani, Profluent cofounder and CEO, said in a statement. “Our success points to a future where AI precisely designs what is needed to create a range of bespoke cures for disease.”


Scientists have developed the world's first working artificial womb


AI was at the heart of this achievement, with the company training Large Language Models (LLMs) on massive scale sequence and biological context. The Profluent team developed a database of 5.1 million Cas9-like proteins, and the AI model was trained on this database to create potential proteins for CRISPR use.

This enabled the LLM to create novel gene editors from scratch as it learned through examples found in nature. After narrowing down the results, they identified OpenCRISPR-1, a protein performing similarly to Cas9 but with far less impact on off-target sites. This makes it more precise and causes minimal damage to DNA.

The goal of open-sourcing OpenCRISPR-1 is to encourage the use of AI for ethical research and commercial use, particularly in developing medicines leveraging CRISPR.


Mark Zuckerberg shows off Jarvis, the AI that runs his home


“We believe by doing so, we can help accelerate the pace of discovery and innovation in the field,” Madani said. “Our vision is to move biology from being constrained by what can be achieved in nature to being able to use AI to design new medicines precisely according to our needs.”

He added that the company intends to partner with cutting-edge research institutions and drug developers working across the drug development life cycle to enable CRISPR medicines to become available to a greater number of patients and for a greater number of disorders.

Gene-editing technologies, including SHERLOCK and DETECTR, are transforming digital diagnostics, enabling rapid detection of infectious diseases such as COVID-19.


Elon Musk targets full global energy transition with Master Plan 3


Companies such as Atomwise, Deep Genomics and Valo are incorporating gene editing into drug discovery processes, revolutionizing treatment development.

Beyond gene editing, AI is powering everything from bone marrow analysis software to drug discovery and platforms to help pair patients with the right cancer-treatment drugs.

Related Posts

Leave a comment


1000's of articles about the exponential future, 1000's of pages of insights, 1000's of videos, and 100's of exponential technologies: Get The Email from 311, your no-nonsense briefing on all the biggest stories in exponential technology and science.

You have Successfully Subscribed!

Pin It on Pinterest

Share This